• 出版社/出版日：Mordor Intelligence / 2018年4月
|Single User（1名様用）||￥459,000 (USD4,250)||▷ お問い合わせ|
|Team User（7名様用）||￥486,000 (USD4,500)||▷ お問い合わせ|
|Corporate User||￥945,000 (USD8,750)||▷ お問い合わせ|
The global cardiac assist devices market is expected to witness a CAGR of 8.5% during the forecast period (2018-2023). In the segmentation based on products type, ventricular assist devices are expected to dominate the global market.
Increasing Advancements in Technology
The continuously rapid advancements in the assist devices technologies and the novel applications of the existing treatments have led to an increase in the cardiac assist devices. In March 2015, FDA approved the Impella 2.5 System, which helps the patients in maintaining a stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures. Engineers are also exploring many other innovative solutions which helps in the implant success and is driving the cardiac assist devices market. Hence, the market is dependent upon the large number of innovations for growth.
Other factors responsible for the market growth are lack of donor’s hearts for transplantation, aging population, and increasing heart diseases, these factors are leading to the increase in cardiac assist devices implantations in patients with severe heart complications.
High Costs of the Instruments
The cardiac assist devices are highly expensive. The high costs of the devices and the low per capita income in the developing and underdeveloped countries is likely to impede the market of cardiac assist devices in low-income countries. The healthcare facility in these countries is still not well developed and advanced technologies are not affordable for the population owing to the high cost, thereby, restraining the growth of the market.
Other factors such as availability of alternative treatments, like pacemakers, and the risk associated with device implantation also hindering the market growth.
North America is leading the Market
North America is the leading market because of the high rate of heart failure cases that are being diagnosed every year. Europe holds the second largest market is owing to the increasing geriatric population. The APAC regions have a large number of underserved patients suffering from cardiac diseases, hence, they represent an attractive future market for cardiac assist devices.
Key Developments in the Market
• August 2017: Abbott introduced HeartMate 3 Left Ventricular Assist System, the latest milestone in therapy for advanced heart failure patients.
Major Players: ABIOMED INC., BERLIN HEART GMBH, BIOHEART INC., BIVACOR PTY LTD, BRAILE BIOMEDICA LTD, CALON CARDIO-TECHNOLOGY LTD, CARDIAC ASSIST INC., CARDIOBRIDGE GMBH, CIRCULITE INC., AND CARDIOKINETIX INC., amongst others.
Reasons to Purchase this Report
• Current and future cardiac assist devices market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• Analysis on the segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3-month analyst support, along with the Market Estimate sheet (in Excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our analyst, who will ensure you get a report that suits your needs.レポート目次
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Advancements in Technology
6.1.2 Aging Population
6.1.3 Increasing Heart Disease Prevalence
6.1.4 Shortage of Heart Donors in Transplantation
6.2 Market restraints
6.2.1 Expensive Instrument and Maintenance
6.2.2 Availability of Alternative Treatments like Pacemakers
6.2.3 Risk Associated with Device Implantation
6.4 Key Challenges
7. Market Segmentation
7.1 -By Product
7.1.1 Intra-Aortic Balloon Pumps
7.1.2 Total Artificial Heart
7.1.3 Ventricular Assist Devices
184.108.40.206 Left Ventricular Assist Device
220.127.116.11 Right Ventricular Assist Device
18.104.22.168 Bi-Ventricular Assist Device
22.214.171.124 External Ventricular Assist Device
7.2 -By Geography
7.2.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 Australia & New Zealand
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
7.2.4 Middle East & Africa
126.96.36.199 South africa
188.8.131.52 Rest of the Middle East & Africa
7.2.5 South america
184.108.40.206 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key players
9.1 Abiomed Inc.
9.3 Berlin Heart Gmbh
9.4 Bioheart, Inc.
9.5 Bivacor Pty Ltd
9.6 Braile Biomedica Ltd
9.7 Calon Cardio-Technology Ltd
9.8 Cardiac Assist, Inc.
9.9 Cardiobridge GmbH
9.10 Circulite, Inc.
9.11 Cardiokinetix, Inc.
9.12 List not exhaustive
10. Future of the market